Jan 8, 2025

Strategy | Financing Transactions Private Placement / Financing Transactions Alzheon: The company raised $125 million of Series E venture funding in a deal led by Alerce Medical Technology Partners on January 2, 2025. The company is a developer of a small molecule-based drug discovery platform designed to treat Alzheimer’s disease and other neurodegenerative disorders. Francis Medical: The company raised $40 million of venture funding from undisclosed investors on December 31, 2024. The company is a developer of novel treatments designmed to treat cancer in the prostate gland, urinary bladder, and kidney. Cytrellis: The company raised $25.1 million of venture funding from undisclosed investors on December 31, 2024. The company is a developer of an aesthetic technology designed to eliminate skin-related problems without any surgery. Ataraxis: The company raised $20 million of venture funding from undisclosed investors on January 3, 2025. The company is a developer of prognostic and predictive digital diagnostic assays designed to help doctors select optimal treatment for patients. General Proximity: The company raised $16 million of venture funding in a deal led by Aydin Senkut on December 18, 2024. Wilson Sonsini Goodrich & Rosati, Alexander Thompson Arnold, Modi Ventures, Age 1, Y Combinator, Jeff Dean, Uri Lopatin, Ben Kohlmann, Alec Nielsen, Trevor Martin, Juan Benet, Nish Bhat and Jimmy Dahlsten Fund also participated in the round. The company is an operator of a biotech business intended to develop drugs that activate existing cellular mechanisms. MediView: The company raised $14 million of venture funding from undisclosed investors on January 3, 2025. The company is a developer of an extended reality surgical navigation technology designed to maximize the accuracy and efficacy of cancer therapies. Auron Therapeutics: The company raised $13.4 million of Series B venture funding from undisclosed investors on December 31, 2024. Putting the company’s pre-money valuation at $144.6 million. The company is an operator of a biotechnology business intended to research and develop products focusing on immunology and oncology. Credence MedSystems: The company raised $12.7 million of Series C venture funding from undisclosed investors on December 30, 2024, putting the company’s pre-money valuation at $173.3 million. The company is a developer of innovative injectable drug delivery devices. Topo Therapeutics: The company raised $10.6 million of venture funding from undisclosed investors on December 31, 2024. The company is a developer of small molecule therapeutics intended to accelerate transmembrane protein drug discovery. Cyclarity Therapeutics: The company raised $10.3 million of Series A venture funding from Ki Tua Fund, VitaDAO, and other undisclosed investors on December 30, 2024, putting the company’s pre-money valuation at $24 million. The company is a developer of compound-based drugs designed to treat the underlying causes of age-related diseases. Man & Science: The company raised EUR 5.3 million of venture funding from undisclosed investors on December 31, 2024, putting the company’s pre-money valuation at EUR 20.4 million. The company is an operator of a medical device business that develops innovative treatments for headache disorders. Cyrus Biotechnology: The company raised $3.2 million of venture funding from undisclosed investors on December 30, 2024. The company is an operator of a biotech business designed to combine protein design and screening to create novel biologics for serious unmet medical needs. BIOHM Health: The company raised $3 million of venture funding from undisclosed investors on December 31, 2024. The company is a manufacturer of health products and kits intended to improve the gut microbiome. Admera Health: The company raised an undisclosed amount of venture funding from Ampersand in January 2025. The company is an operator of a molecular diagnostics center intended to support preclinical development and offer research-grade next-generation sequencing and bioinformatic services. Hura Imaging: The company raised an undisclosed amount of venture funding from Device of Tomorrow Capital in January 2025. The company is an operator of a medical imaging software business intended to provide AI-based innovations for imaging-guided treatment. PreComb: The company raised an undisclosed amount of Series A venture funding in a deal led by Koodos on December 30, 2024. The company is a biotech business developing proprietary technologies to enable evidence-based treatment decisions for cancer. M&A Transactions Windstar Medical / Merz Pharma: The company was acquired by Merz Pharma for EUR 289 million on January 1, 2025. The company is a manufacturer of branded OTC pharmaceutical products. Marinus Pharmaceuticals / Immedica Pharma: The company entered into a definitive agreement to be acquired by Immedica Pharma, via its financial sponsors KKR and Impilo, through a $151 million LBO on December 30, 2024. Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Bioness / Accelmed: The company, a subsidiary of Bioventus, was acquired by Accelmed through a $45 million LBO on January 2, 2025. The company is a developer of non-invasive medical devices intended to help individuals with neurological impairments regain their independence. Carebook Technologies / UIL Finance: The company entered into a definitive agreement to be acquired by UIL Finance through a public-to-private LBO on January 2, 2025 for an undisclosed amount. Carebook Technologies Inc is engaged in the development and commercialization of digital health platforms that feature assessment, reporting, and targeted solutions via selected partners and resellers. Oxular / Regeneron Pharmaceuticals: The company was acquired by Regeneron Pharmaceuticals for an undisclosed amount on January 2, 2025. The company is an operator of a therapeutics business intended to offer retinal disease treatment. Source: Pitchbook Data, Inc.